Immunovant

Committed to engineering transformative therapies for autoimmune diseases

Immunovant is focused on enabling normal lives for patients with autoimmune diseases. The company is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Status
NASDAQ: IMVT
Year of Investment
2021
Strategy
Life Sciences
Location
New York, New York